Delving into the Latest Updates on Vitrisa Therapeutics, Inc. with Synapse

Overview

PEGylation is a common modulator of pharmacokinetics for therapeutic agents in vivo. In this issue of Cell Chemical Biology, Moreno et al. (2019) show anti-PEG antibodies may directly inhibit the activity of a PEGylated aptamer, RB006, both in vitro and in vivo, and the issues surrounding anti-PEG antibodies are discussed.

01 Jun 2018·Nucleic acid therapeutics

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape

Author: Levy, Matthew ; Dowdy, Steven F.

100 Deals associated with Vitrisa Therapeutics, Inc.

Login to view more data

100 Translational Medicine associated with Vitrisa Therapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

VIT-7L-188 ( Ang2 )	Retinal Diseases More	Pending
Anti-VEGF-A aptamer (Vitrisa Therapeutics) ( VEGFR )	Retinal Diseases More	Pending
Anti-IL-8 aptamers (Vitrisa Therapeutics) ( IL-8 )	Neovascularization, Pathologic More	Pending